CDEK
← All drugs Report issue

vestipitant

Small moleculeexperimental

Vestipitant (INN) is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It is under development as a potential antiemetic and anxiolytic drug, and as a treatment for tinnitus and insomnia. — Wikipedia

Clinical trial activity

9 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
8
Phase 3
0
Phase 4
0

Earliest trial started Nov 1, 2002 (NCT00048204)

Timeline

2000s

  1. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1cc(F)ccc1[C@H]1CNCCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Mol. weight
491.45 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 1-piperazinecarboxamide, n-((1r)-1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-2-(4-fluoro-2- methylphenyl)-n-methyl-, (2s)-
  • gw597599
  • gw597599
  • gw597599
  • gw-597599
  • gw597599b
  • vestipitant
  • vestipitant
  • vestipitant
  • vestipitant
  • vestipitant

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01507194Phase 2Feb 1, 2012Accenture, GlaxoSmithKline
NCT01290133Phase 1May 1, 2011Accenture
NCT00992160Phase 2May 1, 2009GlaxoSmithKline
NCT00606697Phase 2Dec 1, 2007GlaxoSmithKline
NCT00394056Phase 2Dec 1, 2006GlaxoSmithKline
NCT00600990Phase 2Dec 1, 2004GlaxoSmithKline
NCT00403962Phase 2Nov 1, 2004GlaxoSmithKline
NCT00343707Phase 2Nov 1, 2004GlaxoSmithKline
NCT00048204Phase 2Nov 1, 2002GlaxoSmithKline
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit8712002
AccentureFor profit2222011
2 organizations
Page 1 / 1